Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 1-Year Low at $103.01

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) hit a new 52-week low on Thursday . The company traded as low as $103.01 and last traded at $107.02, with a volume of 161874 shares. The stock had previously closed at $110.31.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on JAZZ shares. UBS Group cut their target price on Jazz Pharmaceuticals from $135.00 to $131.00 and set a "neutral" rating on the stock in a research note on Friday, March 1st. Stifel Nicolaus boosted their target price on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a "buy" rating in a research note on Friday, March 15th. Piper Sandler boosted their target price on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 20th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $180.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Finally, StockNews.com upgraded Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, January 30th. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $195.25.

Jazz Pharmaceuticals Trading Down 0.9 %

The firm's 50-day simple moving average is $117.26 and its 200-day simple moving average is $121.36. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37. The firm has a market capitalization of $6.89 billion, a PE ratio of 18.02, a price-to-earnings-growth ratio of 1.53 and a beta of 0.63.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The business had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1.01 billion. Equities analysts expect that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares in the company, valued at $1,000,668.96. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares of the company's stock, valued at $1,000,668.96. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Philip L. Johnson purchased 12,000 shares of the firm's stock in a transaction that occurred on Friday, March 1st. The stock was bought at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the purchase, the chief financial officer now owns 27,932 shares of the company's stock, valued at $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Rise Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company's stock valued at $26,000 after purchasing an additional 203 shares in the last quarter. Cape Investment Advisory Inc. increased its position in shares of Jazz Pharmaceuticals by 14,600.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company's stock valued at $36,000 after acquiring an additional 292 shares in the last quarter. Covestor Ltd increased its position in shares of Jazz Pharmaceuticals by 676.5% during the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company's stock valued at $51,000 after acquiring an additional 345 shares in the last quarter. Assetmark Inc. increased its position in shares of Jazz Pharmaceuticals by 37.1% during the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company's stock valued at $54,000 after acquiring an additional 119 shares in the last quarter. Finally, Spire Wealth Management increased its position in shares of Jazz Pharmaceuticals by 128.6% during the third quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company's stock valued at $55,000 after acquiring an additional 238 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.